Term
| Neuromuscular blocking drugs |
|
Definition
| Succinylcholine, Pancuronium (curare) |
|
|
Term
| Succinylcholine: structure and pharmacokinetics |
|
Definition
| 2 Ach molecules end-to-end that cannot be hydrolyzed; quaternary amine (poor oral bioavailability, no CNS entry) |
|
|
Term
|
Definition
| Nicotinic cholinergic receptor |
|
|
Term
| Succinylcholine: mechanism |
|
Definition
| Persistant agonist because it cannot be hydrolyzed by AChE. Depolarizing blockade. Short acting |
|
|
Term
| Pancuronium: structure and pharmacokinetics |
|
Definition
| 2 ACh molecules on steroid nucleus; quaternary amine (poor bioavailability, no CNS entry |
|
|
Term
|
Definition
| Nicotinic receptor competitive antagonist. Non-depolarizing receptor blockade |
|
|
Term
| Pancuronium: adverse effects |
|
Definition
| respiratory paralysis, hypotension (weak ganglion block and histamine release) |
|
|
Term
| Succinylcholine: adverse effects |
|
Definition
| respiratory paralysis, bradycardia (weak ganglionic stimulation), prolonged apnea (pseudocholinesterase-degrades succinylcholine-deficiency), malignant hyperthermia (ryanodine receptor defect), hyperkalemia (burn pts, may cause arrhythmias) |
|
|
Term
| Neuromuscular blocking drug: uses |
|
Definition
| skeletal muscle relaxation during surgery |
|
|
Term
|
Definition
| tertiary amine (better bioavailability and entry into CNS, eye than ipratropium) |
|
|
Term
|
Definition
| competitive antagonist of muscarinic cholinergic receptor |
|
|
Term
| Muscarinic antagonists: classes |
|
Definition
| atropine, benzotropine, scopolamine, ipratropium, tiotropium |
|
|
Term
| Muscarinic Antagonist: uses |
|
Definition
| Parkinson's, motion sickness, asthma/COPD, post-MI bradycardia, traveller's diarrhea, bladder incontinence, to cause mydriasis and cycloplegia |
|
|
Term
| Muscarinic antagonist: adverse effects |
|
Definition
| hyperthermia, intraocular pressure, urinary retention, hallucinations, cycloplegia, dry mouth, flushed skin |
|
|
